Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
News-Medical.Net on MSN
Newly discovered survival pathway explains stubborn EGFR-driven lung cancers
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...
The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...
In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...
Retrospective review of 33,850 molecularly profiled ovarian cancer samples from real-world patients who underwent next-generation sequencing (NGS) of DNA between 2016 and 2025. EGFR-mutated cases were ...
Melissa B. Davis uses CRISPR screening to better understand how cancer affects underrepresented populations and find new potential therapeutic targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results